The Exchange has sought clarification from Ajooni Biotech Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Ajooni Biotech to explain why its financial results for the quarter ended 31 March 2025 do not follow the format prescribed by SEBI under Regulation 33 of the Listing Regulations. The company has not yet submitted its response. Until the exchange receives a satisfactory reply, the matter remains open. This is a routine compliance-related query, not a penalty or enforcement action.
This is a minor procedural compliance issue and is unlikely to materially affect the stock price. However, a delayed or unsatisfactory response could lead to further action by the exchange, so shareholders should watch for the company's clarification.